menu search

Hookipa pharma reports first quarter 2023 financial results and recent business highlights

HOOKIPA on track to report Phase 2 data on HB-200 for head and neck cancer in combination with pembrolizumab in 2Q 2023 Phase 1 clinical trials initia...

May 11, 2023, 11:01 am

Mirati's krazati: a strong competitor in the kras g12c-mutated nsclc market

Mirati Therapeutics specializes in developing cancer treatments targeting genetic and immunological causes, with Krazati being their first FDA-approve...

March 20, 2023, 3:43 am

Meta platforms may see its biggest opening yet for new highs

Both TikTok and META platforms (NASDAQ: META) are social networking platforms that let users make and post brief videos with their followers. Despite ...

March 9, 2023, 1:01 am

Context therapeutics says clinical partner stemline therapeutics receives fda approval for orserdu to treat certain breast cancers

Context Therapeutics (NASDAQ:CNTX) has announced that its clinical trial collaborator, Stemline Therapeutics Inc, a wholly-owned subsidiary of The Me...

January 31, 2023, 8:33 am

Mirati's (mrtx) krazati gets breakthrough therapy tag for crc

The FDA bestows a Breakthrough Therapy designation to Mirati's (MRTX) Krazati (adagrasib) for treating patients with advanced, KRAS-...

December 22, 2022, 12:48 pm

Mirati (mrtx) up on fda nod to adagrasib for kras mutated nsclc

The accelerated approval of Mirati Therapeutics' (MRTX) Krazati is based on ORR and DOR data from the phase II registration-enabling cohort of the KRY...

December 13, 2022, 7:32 am

Mirati's (mrtx) stock rallies 11% on buyout speculations

Mirati Therapeutics' (MRTX) new drug application (NDA), seeking approval for adagrasib, its KRAS inhibitor drug, for previously-treated KRASG12C-...

November 24, 2022, 12:02 pm

Nuvectis pharma, inc. reports third quarter 2022 financial results and business highlights

The dose escalation portion of the Phase 1 clinical trial of NXP800 is ongoing, and the Phase 1b dose expansion portion is expected to begin in Q1 202...

November 8, 2022, 1:00 pm

Cardiff oncology: upcoming readouts and several green lights

Cardiff Oncology started taking a beating from the early days of the biotech bear market, in September 2021. The company is the first to correctly tar...

June 7, 2022, 10:51 am

Astrazeneca, merck's lynparza cut risk of breast cancer death

Treatment with AstraZeneca (AZN) and Merck's (MRK) Lynparza show meaningful improvement in overall survival for patients with BRCA-...

March 17, 2022, 2:18 pm

Astrazeneca, merck's lynparza gets fda nod for expanded use

FDA approves AstraZeneca (AZN) and Merck's (MRK) Lynparza for BRCA-mutated HER2-negative high-risk earl...

March 14, 2022, 12:02 pm

Cardiff: a long-term biotech to own based on overcoming cancer resistance

Cardiff has done well in a Phase 2 study using onvansertib + FOLFIRI + Avastin in treating KRAS-mutated...

March 1, 2022, 4:57 pm

Cardiff: a long-term biotech to own based on overcoming cancer resistance

Cardiff has done well in a Phase 2 study using onvansertib + FOLFIRI + Avastin in treating KRAS-mutated...

March 1, 2022, 4:57 pm

Cardiff: a long-term biotech to own based on overcoming cancer resistance

Cardiff has done well in a Phase 2 study using onvansertib + FOLFIRI + Avastin in treating KRAS-mutated...

March 1, 2022, 4:57 pm

Cardiff oncology to present at the b. riley securities 2022 oncology conference

SAN DIEGO, Jan. 20, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology company, developing new precision medicine ...

January 20, 2022, 1:46 pm

Cardiff oncology to present at the b. riley securities 2022 oncology conference

SAN DIEGO, Jan. 20, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology company, developing new precision medicine ...

January 20, 2022, 1:46 pm

Cardiff oncology to present at the b. riley securities 2022 oncology conference

SAN DIEGO, Jan. 20, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology company, developing new precision medicine ...

January 20, 2022, 1:46 pm

Amgen's lumakras approved in japan for pretreated lung cancer patients

Amgen Inc's (NASDAQ: AMGN) Lumakras (sotorasib) has been approved in Japan for KRAS G12C-mutated pos...

January 20, 2022, 8:52 am

Amgen's lumakras approved in japan for pretreated lung cancer patients

Amgen Inc's (NASDAQ: AMGN) Lumakras (sotorasib) has been approved in Japan for KRAS G12C-mutated pos...

January 20, 2022, 8:52 am

Amgen's lumakras approved in japan for pretreated lung cancer patients

Amgen Inc's (NASDAQ: AMGN) Lumakras (sotorasib) has been approved in Japan for KRAS G12C-mutated pos...

January 20, 2022, 8:52 am


Search within

Pages Search Results: